"AstraZeneca’s Phase III trial of treatment for asthma meets its primary endpoint" was originally created and published by ...

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire ...

Airsupra (PT027), a new asthma rescue treatment developed by AstraZeneca (AZ) and development partner Avillion, has been approved by the US Food and Drug Administration (FDA). A first-in-class ...

The companies did not provide detailed data for Tezspire, however, and William Blair’s Matt Phipps said in a note he does not ...

AstraZeneca (NASDAQ:AZN)'s AIRSUPRA, an inhaled anti-inflammatory medication, has shown promising results in a Phase IIIb trial by significantly reducing the risk of severe asthma exacerbations ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics ...

AstraZeneca and GlaxoSmithKline produce ... Take the market for albuterol inhalers, filled with fast-acting drugs meant to stop an asthma attack in its tracks. Before the propellant switch ...

Asthma treatment primarily focuses on managing ... For example, in December 2021, Amgen Inc. and AstraZeneca announced that the U.S. Food and Drug Administration (FDA) approved TEZSPIRE ...

The Asthma Society of Ireland says new research, commissioned by AstraZeneca, into the dispensing of steroid tablets across Irish retail pharmacies, highlights the over reliance on the medication ...

WILMINGTON, Del. - AstraZeneca (NASDAQ:AZN)'s AIRSUPRA, an inhaled anti-inflammatory medication, has shown promising results in a Phase IIIb trial by significantly reducing the risk of severe asthma ...